Elevage Medical Technologies Appoints Michael Wasserman as CEO

Wasserman replaces Evan Melrose, M.D., who has been removed from all roles at Elevage, its Board of Directors and the companies it has partnered with.

The company’s strategy, investment approach and support for its partner companies will remain unchanged. Dr. Wasserman brings more than 30 years of experience in healthcare as a scientist, entrepreneur, executive and investor.

Read More:Sharp Biomedical Raises Pre-Seed Funding Led by Gener8tor

Before joining Elevage, he was Managing Partner at Maverix Private Equity and spent 17 years as a Managing Director at H.I.G. Capital, where he worked in the firm’s BioHealth platform.

He has worked with management teams and portfolio companies on research and development, product development, commercialization, financing and business strategy. He has also served on the boards of several growing medical technology companies.

“I am honored to lead Elevage and continue our mission of helping innovative medical technology companies navigate critical growth stages,” said Dr. Wasserman. “Our focus remains on partnering with exceptional management teams and providing the capital, strategic support and operational expertise that help breakthrough technologies reach more patients and improve health outcomes and quality of life.”

“Elevage currently has meaningful momentum, and Michael has been instrumental in shaping the culture and approach since he joined at inception,” said Jim Momtazee, Chairman of the Board of Directors of the Company. “We have a lot of confidence in Michael and the entire team at Elevage and look forward to continuing to aid in the expansion of a number of promising medical technologies.”

About Elevage Medical Technologies

Founded in 2023, Elevage Medical Technologies was established by Patient Square Capital to support medical technology companies developing products that can improve patient health and quality of life. The company provides funding along with technical, regulatory and operational support to medical technology businesses at different stages, from clinical development to commercial growth.

Read More:Hormel Foods Appoints Holly LaVallie as Vice President